New pill could extend dogs’ lives, giving owners more time with their pets

(SeaPRwire) –   For many pet owners, the most difficult aspect of having a dog is the foreknowledge of the inevitable farewell.

A San Francisco-based startup named Loyal aims to provide a few more valuable moments with your faithful friend, and their findings are encouraging.

The company is creating a daily prescription medication for older dogs that it is confident can increase your pet’s healthy years by focusing on a primary cause of aging: metabolic dysfunction.

“While arthritis, cancer, and cognitive decline are distinct conditions,” explained Dr. Brennen McKenzie, Loyal’s director of veterinary medicine, “aging and metabolic health represent a core factor that influences all of them.”

He explained that the strategy is to address the source of the problem instead of reacting to each illness as it appears.

“By targeting the common underlying mechanism for all these issues, we can achieve a far greater improvement in health, welfare, and overall wellbeing than by tackling each disease individually,” he stated.

The medication, LOY-002, functions as a caloric restriction mimetic, replicating certain advantages of a very low-calorie diet without the difficulty—or for beagle owners, the challenge—of denying food to your pet.

“The cleverness of LOY-002 is that it delivers similar biological outcomes as caloric restriction, but without the associated challenges and risks,” McKenzie said, citing a key Purina study where dogs on restricted calories lived about two years longer on average. “It avoids the need to cut calories and does not lead to weight loss.”

Loyal has described its STAY study as the biggest clinical trial in veterinary history, enrolling 1,300 dogs from 72 clinics across the country in a randomized, double-blind, placebo-controlled format.

“We are administering either the drug or a placebo and conducting extremely close monitoring, gathering a vast amount of compelling data,” McKenzie said. “Ultimately, we hope to observe that the dogs receiving the drug live longer, experience less frailty, have an improved quality of life, and hopefully develop fewer age-related diseases.” The study is currently two and a half years into a minimum four-year duration.

Importantly, LOY-002 might become available before the STAY study finishes. Loyal is seeking conditional approval from the FDA, a pathway intended for drugs that have met safety standards but are still under long-term efficacy review.

“The FDA understands that these studies are lengthy, taking many years to complete,” McKenzie noted. “Currently, no drug exists to address this issue. There is nothing available that targets aging to help dogs live longer. So, if we can demonstrate safety and a strong likelihood of effectiveness, we can make it available to veterinarians and owners more quickly.”

Regarding the potential extension of life, McKenzie was cautious: “Specific numbers are always difficult, as people tend to focus on them and assume they are more certain than they actually are.”

He mentioned that early data from the STAY study has shown a difference of at least one year between the group receiving the treatment and the placebo group.

“I don’t believe we can promise a specific number of extra years or months with your dog,” McKenzie added. “Our goal is to demonstrate a meaningful overall increase that makes a real difference.”

The ambitious scale of the trial signaled its serious intent.

“When we announced a goal of enrolling 1,000 dogs, everyone told us, ‘You’re crazy. A study that large has never been done. It’s impossible,'” McKenzie recalled. Ultimately, more than 12,000 people emailed Loyal seeking to participate. “Many said, ‘I know this might not help my current dog, but the chance to contribute to a future where dogs have more time is incredibly motivating.'”

Concerning human applications, McKenzie emphasized that the drug should be seen not as a biohack or a quick fix for longevity, but as an advancement in preventive medicine.

“This isn’t a hack or a simple trick,” he clarified. “It’s about applying a fundamental understanding of aging biology to practice better preventive medicine.”

He believes that success in dogs could pave the way for similar treatments for people.

“If this drug is approved, it will be the first anti-aging or lifespan-extending drug ever approved for any species,” he said. “I hope it opens scientific doors by demonstrating a viable path to proving this approach works.”